Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
α-Lactalbumin nanomicelles in obese mice
A mouse study tested sulforaphene-loaded α-lactalbumin nanomicelles against semaglutide, but it provides no human efficacy or safety evidence.
Australia GLP-1 access trends, 2020-2025
Australian sales and PBS data show rapid GLP-1 medicine growth, with nearly half of estimated use accessed privately in the final study year.
Diabetes kidney prevention: German model
A German model found semaglutide cost-effective for kidney prevention, while tirzepatide gained more health at a much higher modeled cost.
Oral semaglutide for alcohol use disorder
A 50-person randomized trial missed its primary craving endpoint but found signals on heavy drinking days and other secondary measures.
Oral semaglutide and arterial stiffness
A retrospective cohort linked higher-dose oral semaglutide and SGLT-2 inhibitor use with improved arterial stiffness, without proving causation.
PCSK1 Obesity: Two GLP-1 Cases
Two sisters with a loss-of-function PCSK1 mutation lost 16% to 27% of body weight on GLP-1-based treatment, raising a mechanism question.
Peptides in sexual medicine: evidence
A 2026 review separates approved bremelanotide evidence from early kisspeptin research and unsupported claims for growth hormone peptides.
Semaglutide MASH Cost-Effectiveness Model
A 2026 US payer model projected semaglutide as cost effective for non-cirrhotic MASH, but lifetime results depend on assumptions and sponsor inputs.
Tirzepatide and Pneumatosis Intestinalis
A 2026 case report links tirzepatide exposure with histologically confirmed pneumatosis intestinalis in one patient, without proving general risk.
CagriSema REDEFINE 1 Target Analysis
A post hoc REDEFINE 1 analysis found more CagriSema participants reached BMI and waist-to-height targets, but the cutoffs need prospective validation.
GLP-1 Cardiovascular Umbrella Review
A 2026 umbrella review found stronger cardiovascular evidence in people with established disease, with more limited tirzepatide-specific certainty.
GLP-1 Drugs and NAION: A 2026 Review
A 2026 review found a rare NAION safety signal around GLP-1 medicines, led mainly by observational semaglutide data.